http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
손보형,이효빈,황호길,윤창륙,여환호 大韓顎顔面成形再建外科學會 1992 Maxillofacial Plastic Reconstructive Surgery Vol.14 No.4
The author investigated the 162 patients with the condylar fractres of the mandilble who were admitted in Dept. of Oral and Maxillofacial Surgery, Hospital of Chosun Dental School from January 1985 to September 1992 clinically, including fracture incidennce, age and sex of the patients, causes of injures, associated injures, treatments and complications and obtained the following results. 1. Of the 449 patients with mandibular fractures, 162patients suffered condylar fractures(36.1%). 2. Of the 162 patients, males with condylar fractures were 128 patients, by a ratio of 3.8 : 1. 3. The most frequently affected age group was the third decade(32.7%). 4. Falls were ranked as the predominant cause(50.6%), followed by traffic accident(27.8%) and violence (16.0%). 5. The incidence of single condylar fractures was 28% and symphysis fractures were the most commomest of the concomittant injuries(60%). 6. The subcondylar fractures occurred most frequently(41.6%) and anteromedial displacement of the condylar fragments occurred most frequently(45.4%) 7. Of the all condylar fracture patients, children under 15 of age comprized 31 patients(19.1%) and condylar head fractures occurred most frequently at those children. 8. Of the managetments in condylar fractures, open reduction was 52.5% and remainder were closed reduction(47.5%). 9. Complications ensured such as TMJ ankylosis, limitation of mouth opening and mandibular movements, TMJ dysfunction, and anterior open bite.
Characterization of the aminopyridine derivative KRC-180 as a JAK2 inhibitor
Yoon, Kyoung Bin,Cho, Sung Yun,An, Su Jin,Park, Kyeong Ryang,Lee, Hyo Jeong,Yoon, Hae Sung,Lee, Sun-Mi,Kim, Yong-Chul,Han, Sun-Young D.A. Spandidos 2017 Oncology letters Vol.14 No.2
<P>Janus kinase 2 (JAK2) is a non-receptor tyrosine kinase that regulates the signal transducer and activator of transcription (STAT) signaling pathway. Deregulation of JAK2 signaling has previously been observed in hematologic malignancies, including erythroleukemia. In the present study, an aminopyridine derivative compound, KRC-180, exhibited direct inhibition of the JAK2 protein at the catalytic site, as demonstrated using <I>in vitro</I> kinase activity assays and docking analyses. In addition, KRC-180 reduced the phosphorylation of STAT3 and STAT5, downstream signaling molecules of JAK2. The growth of HEL92.1.7 erythroleukemia cells harboring a constitutively activated form of JAK2 was suppressed by KRC-180 treatment; KRC-180 induced apoptotic cell death and cell cycle arrest. The results of the present study indicate that KRC-180 is a JAK2 inhibitor with anti-leukemic properties.</P>
Yoon, Hoi Soo,Im, Ho Joon,Moon, Hyung Nam,Lee, Jae Hee,Kim, Hee-Jin,Yoo, Keon Hee,Sung, Ki Woong,Koo, Hong Hoe,Kang, Hyung Jin,Shin, Hee Young,Ahn, Hyo Seop,Cho, Bin,Kim, Hack Ki,Lyu, Chuhl Joo,Lee, M Blackwell Publishing Ltd 2010 Pediatric transplantation Vol.14 No.6
<P>Yoon HS, Im HJ, Moon HN, Lee JH, Kim H-J, Yoo KH, Sung KW, Koo HH, Kang HJ, Shin HY, Ahn HS, Cho B, Kim HK, Lyu CJ, Lee MJ, Kook H, Hwang TJ, Seo JJ. The outcome of hematopoietic stem cell transplantation in Korean children with hemophagocytic lymphohistiocytosis.Pediatr Transplantation 2010: 14:735–740. © 2010 John Wiley & Sons A/S.</P><P>Abstract: </P><P>Chemoimmunotherapy-based treatments have improved the survival of patients with HLH, but outcomes of the patients are still unsatisfactory. We report here the outcome of Korean children with HLH who underwent HSCT, which was analyzed from the data of a nation-wide HLH registry. Retrospective nation-wide data recruitment for the pediatric HLH patients diagnosed between 1996 and 2008 was carried out by the Histiocytosis Working Party of the Korean Society of Hematology. Nineteen patients who received HSCT among the total of 148 enrolled children with HLH were analyzed for the transplant-related variables and events. The probability of five-yr survival after HSCT was 73.3% with a median follow-up of 57. Two months compared to 54.3% for the patients who were treated with chemoimmunotherapy only (p<I> </I>=<I> </I>0.05). The reasons for HSCT were active disease after eight wk of initial treatment (n = 9), relapsed disease (n = 5), and FHL (n = 5). Fourteen patients are currently alive without disease after HSCT, four patients died of treatment-related events (infection in two and graft failure in two) at early post-transplant period, and one patient died of relapse at one yr post transplantation. The survival of patients who were transplanted because of active disease after eight wk of initial treatment was worse compared to those patients who had inactive state at that time (60.6% vs. 100%, respectively, p<I> </I>=<I> </I>0.06). Of the four patients who received transplants using cord blood, three died of graft failure (n = 2) and relapse (n = 1). The five-yr probability of survival after HSCT according to the donor type was 85.7% for the MRDs (n = 6), 87.5% for the MUDs (n = 8), and 40% for the MMUDs (n = 5) (p<I> </I>=<I> </I>0.03). Other variables such as age, CNS involvement at the time of diagnosis, the etiology of HLH (familial or secondary), and the conditioning regimens had no influence on the five-yr OS of the HLH patients who underwent HSCT. HSCT improved the survival of the patients who had familial, relapsed, or severe and persistent SHLH in the Korean nation-wide HLH registry. Although numbers were small, these results are similar to other reports in the literature. The disease state after initial treatment, the stem cell source of the transplant, and the donor type were the important prognostic factors that affected the OS of the HLH patients who underwent HSCT.</P>
( Hyo Young Lee ),( Yun Bin Lee ),( Jeong-hoon Lee ),( Sungwon Chung ),( Minseok Albert Kim ),( Sun Woong Kim ),( Jun Sik Yoon ),( Young Chang ),( Eun Ju Cho ),( Su Jong Yu ),( Nam-joon Yi ),( Yoon Ju 대한간학회 2018 춘·추계 학술대회 (KASL) Vol.2018 No.1
Aims: We recently developed and validated a MoRAL score (=11 x √PIVKA + 2 x √AFP) that can predict the risk of hepatocellular carcinoma (HCC) recurrence after living-donor liver transplantation (LDLT) regardless of tumor size and number, which may reflect tumor cell biology. Patients with a low MoRAL score (≤ 314.8) showed excellent treatment outcomes after LDLT, even though they are beyond the Milan criteria. We investigated whether a MoRAL score is a predictor of HCC recurrence and mortality after curative hepatic resection. Methods: A total of 662 consecutive patients who underwent curative resection for HCC of BCLC stage 0-B between 2006 and 2013 at a single tertiary referral center were included. Primary and secondary endpoints were recurrence-free survival (RFS) and overall survival (OS), respectively. Results: During a median observation period of 68.8 months, 326 (49.2%) patients experienced tumor recurrence and 59 (8.9%) died. In multivariable analysis, high MoRAL score (>314.8) was an independent risk factor of both recurrence (adjusted hazard ratio [aHR]=1.61, 95% confidence interval [CI]=1.22-2.12, P=0.001) and death (aHR=2.62, 95% CI=1.49-4.59, P=0.001). The presence of cirrhosis was another independent prognostic factor for RFS (aHR=1.76, 95% CI=1.38-2.24, P<0.001) and OS (aHR=1.82, 95% CI=1.06- 3.14, P=0.031). When patients were stratified into four groups as low-MoRAL/no-cirrhosis, low-MoRAL/cirrhosis, high-MoRAL/ no-cirrhosis, or high-MoRAL/cirrhosis; the RFS (Figure 1A) and OS (Figure 1B) significantly differed among strata (all P<0.001). Median RFSs of the high-MoRAL/LC, the low-MoRAL/LC, and the high-MoRAL/no-LC groups were 20.4, 41.8, and 53.2 months, respectively; while the low-MoRAL/no-LC group did not reach median RFS. A MoRAL score showed significant association to hypermetabolism on positron emission tomography (P<0.001, chi-squared test for trend) and cytokeratin 19-positivity in tumor tissue (P=0.003, Pearson chi-square), which reflect aggressive tumor cell biology. Conclusions: A MoRAL score was an independent predictor of tumor recurrence and mortality after curative resection of HCC regardless of tumor size and number and reflects tumor biology. Combination of MoRAL score and the presence of cirrhosis might be utilized as an accurate prediction model.
Hyo-Ju Lee,Ki-Yeop Cho,Semi Oh,So-Yeon Park,Ye-Bin Im,Suyeon Son,Yong-Jin Yoon,Seong-Ju Park,Kyoung-Kook Kim 한국정밀공학회 2021 International Journal of Precision Engineering and Vol.8 No.2
We report on the optical and electrical properties of MgZnO/Ag/MgZnO (MAM) grid electrodes grown at room temperature; these are proposed as an alternative to metal-based grid electrodes to meet the requirement for high stability in a harsh environment. The optical transmittance of Ag grid electrodes improved when the Ag grid layer was embedded in an MgZnO grid layer regardless of the fi ll factor. This improvement depends critically on the Ag grid layer thickness in the MAM grid electrodes. The Haack figure of merit for a MAM grid electrode with a 20 nm-thick Ag grid layer was approximately threefold higher than that of an Ag grid electrode. The electrode has an average transmittance of 85.8% at wavelengths range from 400 to 1100 nm and a sheet resistance of 26.9 Ω/sq. These results indicate that MAM grid electrodes can be an alternative to metal-based grid electrodes in optoelectronic devices that require stable wideband operation in a harsh environment and over a wide wavelength region.
( Hyo Young Lee ),( Eun Ju Cho ),( Sungwon Chung ),( Minseok Albert Kim ),( Sun Woong Kim ),( Jun Sik Yoon ),( Young Chang ),( Yun Bin Lee ),( Jeong-hoon Lee ),( Su Jong Yu ),( Yoon Jun Kim ),( Jung-h 대한간학회 2018 춘·추계 학술대회 (KASL) Vol.2018 No.1
Aims: Recently, the emergence and use of potent immunosuppressive drugs has increased interest in the incidence of hepatitis B virus (HBV) reactivation. However, studies on the factors that predict the HBV reactivation in patients with resolved infection undergoing renal transplantation are insufficient. The aim of this study is to investigate the incidence and potential risk factors for HBV reactivation in kidney transplant (KT) patients with resolved HBV infection. Methods: A consecutive 735 patients who received KT between 1995 and 2010 at a single tertiary referral center were included. Patients who were younger than 20 years old, HBsAg-positive, not available with hepatitis B surface antibody (anti-HBs) or hepatitis B core antibody (anti-HBc) data, and who received combined or previous liver transplantation were excluded. A total of 228 patients were analyzed. HBV reactivation was defined as HBsAg seroreversion or detectable viremia. Results: During a median observation period of 128.9 months, five (2.2%) patients experienced HBV reactivation. The median time to reactivation from KT was 54.7 months. We could not find an association between donor HBV profile and HBV reactivation rate in this study. Also, immunosuppressive therapy was similar in patients with and without reactivation. Multivariable cox regression analysis with Firth’s penalization showed that graft failure (adjusted hazard ratio [aHR] = 39.9, 95% confidence interval [CI] = 6.6-241.5, P<0.001), rejection (aHR=7.9, 95% CI=1.3-47.2, P=0.024) and low anti-HBs titer (≤40 mIU/ ml, aHR=29.27, 95% CI=3.3-3842.7, P<0.001) at baseline were significant predictive factors for HBV reactivation. Conclusions: HBV reactivation rate in KT recipients with resolved infection was low, but not negligible. Monitoring of HBV reactivation may be warranted in patients with low anti-HBs levels, graft rejection or failure.